Barclays Defends VeriFone (PAY); Strong Fundamentals - Buy Shares On Weakness
Tweet Send to a FriendGet Alerts PAY Hot Sheet
Price: $23.19 +3.34%
Rating Summary:
6 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Rating Summary:
6 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Trade PAY Now!
Barclays reiterates an 'Overweight' on VeriFone (NYSE: PAY) price target of $60.00.
Analyst, Darrin D. Peller, said, "...we believe it's important for investors not to miss the forest for the trees. With materially better-than-market top-line growth trends and EPS growth north of 20%, we would highly recommend buying shares on any material weakness in trading today, ahead of what we expect should be solid growth to come."
For an analyst ratings summary and ratings history on VeriFone click here. For more ratings news on VeriFone click here.
Shares of VeriFone closed at $45.00 yesterday, with a 52 week range of $30.25-$55.89.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Darrin D. Peller, said, "...we believe it's important for investors not to miss the forest for the trees. With materially better-than-market top-line growth trends and EPS growth north of 20%, we would highly recommend buying shares on any material weakness in trading today, ahead of what we expect should be solid growth to come."
For an analyst ratings summary and ratings history on VeriFone click here. For more ratings news on VeriFone click here.
Shares of VeriFone closed at $45.00 yesterday, with a 52 week range of $30.25-$55.89.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
- Merck's (MRK) Suvorexant Faces Challenges at FDA
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
BarclaysLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

